Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INO-1001 in high-risk patients undergoing cardiopulmonary bypass
NCT00271167Phase 2Terminated
- Sponsor
- Inotek Pharmaceuticals
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in postoperative complications comparing INO-1001 with Placebo (2 arms). Primary endpoints: Reduction in serious post-operative complications at 30 days, Safety and tolerability at 30 days and 1 more. Started Oct 2005; status: terminated.
02
Drugs
INO-1001
03
Conditions
postoperative complications
Beyond the preview
Go deeper on NCT00271167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00271167.